Thesis as of Aug 3, 2026
CRISPR Therapeutics is a commercial-stage gene-editing company whose lead product, CASGEVY, treats sickle cell disease and beta thalassemia, both serious inherited blood disorders, and is approved for use in children as young as 2.
CASGEVY, approved for children as young as 2 with sickle cell or beta thalassemia, posted Q2 2026 revenue of $76 million, up 78% quarter-over-quarter. Whether global reimbursement access and the pediatric label can scale revenue above operating costs determines the commercial thesis. Allogeneic CAR-T and in vivo gene-editing programs remain early-stage with substantial execution risk across multiple indications.
Current Thesis Drivers
What could change the thesis?
Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.
Thesis log
Tracked in real time as it happened — not reconstructed after the fact
Key value driver
The most decisive event ahead
Bull and bear case
Both sides of the Thesis, argued
Pipeline
24 programs · 13 catalysts